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Tamoxifen prolongs survival and alleviates
symptoms in mice with fatal X-linked myotubular
myopathy
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X-linked myotubular myopathy (XLMTM, also known as XLCNM) is a severe congenital
muscular disorder due to mutations in the myotubularin gene, MTM1. It is characterized by
generalized hypotonia, leading to neonatal death of most patients. No speciﬁc treatment
exists. Here, we show that tamoxifen, a well-known drug used against breast cancer, rescues
the phenotype of Mtm1-deﬁcient mice. Tamoxifen increases lifespan several-fold while
improving overall motor function and preventing disease progression including lower limb
paralysis. Tamoxifen corrects functional, histological and molecular hallmarks of XLMTM,
with improved force output, myonuclei positioning, myoﬁbrillar structure, triad number, and
excitation-contraction coupling. Tamoxifen normalizes the expression level of the XLMTM
disease modiﬁers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue. Our
ﬁndings demonstrate that tamoxifen is a promising candidate for clinical evaluation in
XLMTM patients.
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X-linked centronuclear myopathy (XLCNM; OMIM#310400), the most severe form of centronuclear myo-pathy (CNM), affects ~1 in 50,000 males1. XLCNM is
commonly known as X-linked myotubular myopathy (XLMTM)
as characteristic histological features include small-caliber myo-
ﬁbers and centrally located nuclei resembling myotubes2,3.
XLMTM patients present with profound and generalized muscle
weakness from birth. Most XLMTM male patients die in the ﬁrst
2 years of life; some develop a milder form and may survive into
adulthood while female carriers display a more heterogeneous
disease1,4–6. XLMTM is due to the lack of myotubularin (MTM1),
a lipid phosphatase that dephosphorylates phosphatidylinositol
3-phosphate (PtdIns(3)P) and PtdIns(3,5)P2 into PtdIns and
PtdIns(5)P7–9. Imbalance in these lipids impairs membrane
trafﬁcking, nuclei positioning, and t-tubule organization10.
No speciﬁc treatment exists for XLMTM. AAV-mediatedMTM1
replacement therapy showed great promise in murine and canine
models and has reached clinical stage (ClinicalTrials.gov Identiﬁer:
NCT03199469)11–14. Down-regulating dynamin-2 (DNM2), a
protein mutated in autosomal forms of CNM, is another promising
approach to rescue several CNM forms15–17. The development of
these innovative therapies, however, may be hampered by technical
and safety issues and be further complicated by cost issues in case of
clinical efﬁcacy. By contrast, repurposing well-known drugs might
offer time- and cost-effective therapeutic options18.
Tamoxifen has been used for almost 40 years to treat estrogen
receptor-positive breast cancers in both women and men19–21
and has been tried in a variety of other disorders22–27. Impor-
tantly, tamoxifen proved safe in pediatric patients28–35. Our
earlier published36,37 and unpublished ﬁndings that tamoxifen
potently counteracted the symptoms in a mouse model of
Duchenne muscular dystrophy (DMD) have been translated into
compassionate use and a phase 3 clinical trial in underway on
DMD boys (ClinicalTrials.gov Identiﬁers NCT02835079 and
NCT03354039, respectively).
We thus thought to evaluate tamoxifen in Mtm1−/y mice, a
validated model of XLMTM15,38–40. In the present work, we
demonstrate that oral tamoxifen given to pups from weaning
onwards signiﬁcantly corrects functional, histological, and
molecular hallmarks of the disease, resulting in a remarkable
enhancement in survival. Tamoxifen is the ﬁrst EMA- and FDA-
approved drug to show such a promising therapeutic potential for
patients with XLMTM.
Results
Effects of oral tamoxifen treatments on food and drug intake.
Mtm1−/y mice and wild type (WT) littermates were weaned on
post-natal day 23 ± 1, slightly after disease onset, at which time
they were given a control diet or pellets supplemented with
tamoxifen citrate (equivalent to 30, 10, and 3 mg tamoxifen free
base per kg of diet). Food intake was similar on control and high-
tamoxifen diets throughout the study time for Mtm1−/y and wild
type mice (Supplementary Figure 1). On the highest dose (30 mg
kg−1 of diet), tamoxifen intake was approximately 6, 5, and 4 mg
kg−1 d−1 in treated mice aged 42, 84, and 200 days, respectively.
The levels of tamoxifen and major metabolites in plasma and leg
muscle tissue were consistent with levels found previously in
treated dystrophic mice36 (Supplementary Table 1).
Tamoxifen improves life span and slows disease progression.
Untreated Mtm1−/y mice showed early hind limb paralysis with
rapid progression of muscle weakness to the trunk and forelimbs,
resulting in marked kyphosis, frailty (Fig. 1a) and premature
death at a median age of 45 days (Fig. 1b). By contrast, all doses of
tamoxifen extended the life span of Mtm1−/y mice, which on the
highest dose, reached a median age of 290 days. Shortly before
dying, all untreated Mtm1−/y mice showed paralyzed hindlimbs
and dragging feet. By contrast, adult-treated mice remained
mobile and retained ability to rear and to climb onto objects using
both forelimbs and hindlimbs (Supplementary Movies 1–4).
Remarkably, one Mtm1−/y mouse on high tamoxifen reached
464 days of age. Consistent with tamoxifen-mediated enhanced
survival, disease progression was signiﬁcantly delayed in treated
Mtm1−/y mice (Fig. 1c), which performed almost as well as WT
mice in an anti-gravity assay assessing whole-body force (Fig. 1d).
Old Mtm1−/y mice on high tamoxifen diet presented less clinical
features of disease and relatively spared upper body (Fig. 1a),
suggesting slower retrograde disease progression. This was illu-
strated by the ability of the treated mice to climb onto objects
using their forelimbs, preserved neck and head control, and
relatively large thoracic cage suggestive of spared trunk muscles
(Supplementary Movies 3, 4; Fig. 1a). In spite of overwhelming
protection from the disease, tamoxifen-treated Mtm1−/y mice
remained small (Fig. 1e). Similarly, tamoxifen-treated WT mice
were smaller than their untreated counterparts, partly due to
smaller muscles (Supplementary Tables 2, 3), and presumably
also because of reduced amount of white adipose tissue, which
was evident upon dissection and similar to our observation in
dystrophic mice reported earlier36.
In order to examine the impact of tamoxifen on muscle
mechanical properties, muscle structure and molecular adapta-
tion underpinning tamoxifen-mediated protection, we next
treated mice for various periods with optimal tamoxifen dosing
(30 mg kg−1 of diet).
Tamoxifen improves the size of leg muscles and diaphragm.
Compared with WT mice, most locomotor muscles examined in
Mtm1−/y mice showed severe atrophy at D42 (Supplementary
Table 2, 3). That atrophy was partly prevented by tamoxifen even
after normalization for improved body weight (from +10% in the
quadriceps to +18% in the gastrocnemius). Overall, the effect of
tamoxifen at increasing muscle size of Mtm1−/y mice persisted
until D210. The diaphragm of Mtm1−/y mice showed a distinct
response to tamoxifen: although the diaphragm was atrophic at
D42 and D84, its absolute size doubled between D84 and D210.
As a consequence of changes in body weight, the relative size of
the diaphragm was gradually bigger over time (from 67 to 198%
of wild-type counterparts at D42 and D210, respectively).
Tamoxifen improves the strength and features of leg muscles.
Muscle weakness is a key pathological feature of XLMTM patients
that is also prominent in the Mtm1−/y murine model. We
investigated if and to what extent tamoxifen ameliorated the force
generated by the triceps surae (hereafter referred to as triceps), a
large muscle group of the lower leg that makes up most of the
calf volume and contains gastrocnemius, plantaris, and soleus
muscles.
We ﬁrst analyzed phasic (also known as twitch) force at D42, at
which time a substantial proportion of untreated Mtm1−/y mice
survived. The absolute phasic force of untreated Mtm1−/y mice
was highly compromised, representing only 17.3% of that of
untreated wild-type mice. Tamoxifen signiﬁcantly enhanced the
absolute force of Mtm1−/y mice almost threefold (Fig. 2a). The
absolute phasic traces were normalized to the triceps cross-
sectional area in order to express the speciﬁc phasic tension, i.e.,
the force generated per unit of muscle cross-section (Fig. 2b).
This revealed that tamoxifen markedly augmented the speciﬁc
phasic force of Mtm1−/y mice (+155%), reaching 61% of the
force developed by WT mice. We then compared the speciﬁc
phasic force at D42, D84, and D210 (Fig. 2c). Tamoxifen
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Fig. 1 Tamoxifen rescues the phenotype of XLMTM mice. Life-long oral tamoxifen delays disease progression in XLMTM mice. Wild type (WT) and
Mtm1−/y mice were fed control or tamoxifen (TAM)-supplemented diets from weaning onward. a Photographs of WT and Mtm1−/y mice, illustrating
disease severity in young untreated mice and protection conferred by tamoxifen in adult and old mice. b Kaplan–Meier curves showing the effects of
treatments on mouse survival. Early death of untreated Mtm1−/y mice contrasts with prolongation of life span in tamoxifen-treated littermates. Data are
from 8 to 18 mice per group. *P≤ 0.05; ****P≤ 0.0001. Log-rank (Mantel–Cox) test. c Disease progression was assessed three times per week using a
5-grades clinical scale: muscle function was scored as 1 (normal function of hind limbs), 2 (difﬁculty in spreading toes), 3 (evident weakness in legs), 4
(paralysis of one hind limb), or 5 (complete paralysis of both legs). WT mice had a clinical score of 1 (normal) throughout the study. Untreated Mtm1−/y
mice quickly reached a high clinical grade, whereas disease progressed much slower in tamoxifen-treated littermates. d Mouse motor function was
assessed weekly via a horizontal grid-hanging test. The score of untreatedMtm1−/y mice declined quickly. Tamoxifen preserved motor function ofMtm1−/y
mice close to WT values. e Mouse body weight was recorded 3 times per week. Tamoxifen affected the growth of WT but not of Mtm1−/y mice. Mtm1−/y
mice remained smaller than WT mice throughout. b–e Symbols and TAM doses (0.3, 3, and 30mg kg−1 of diet) are shown on the right-hand side. c, d, e
Data represent the mean ± s.e.m. of 8 to 18 mice as deﬁned in a. *P≤ 0.05; **P≤ 0.01; ****P≤ 0.0001; ns non-signiﬁcant. One-way ANOVA with Fisher’s
least signiﬁcance difference (LSD) post-test
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considerably increased this parameter inMtm1−/y mice at all ages
studied compared to untreated Mtm1−/y mice at D42 (Fig. 2c).
Functional beneﬁts culminated to 74.1% of WT values at D84 and
showed only marginal decrease at D210.
Then, the tetanic forces were determined from force–frequency
curves. Tamoxifen more than doubled (2.1-fold increase) the
absolute tetanic force of Mtm1−/y mice at D42, which, after
correction for muscle size, reached 53.2% of WT values (Fig. 2d,
e). Similar to phasic force, tamoxifen remarkably increased the
speciﬁc tetanic force of Mtm1−/y mice at all ages studied (Fig. 2f).
Maximum beneﬁts were found at D210, when tetanic force
reached 71.7% of age-matched wild type values (68.2% at D84).
Further analysis of the phasic traces revealed a signiﬁcant
reduction in the time required by the triceps of untreated
Mtm1−/y mice for reaching twitch peak force, indicative of
impaired excitation–contraction coupling (Fig. 2g). Tamoxifen
fully restored the time to twitch peak to normal values at all ages.
Tamoxifen did not signiﬁcantly alter the time for half-relaxation
from twitch peak at D42 (indicative of SERCA activity and
kinetics of inactivation of actin–myosin cross-bridges) (Fig. 2h).
Nevertheless, this feature tended to increase with age in both WT
and Mtm1−/y mice treated with tamoxifen.
In striking contrast with its beneﬁcial actions inMtm1−/y mice,
tamoxifen caused generalized muscle hypotrophy in WT mice,
which was only partly explained by decreased body weight
(Supplementary Table 2, 3). In WT triceps at D42, this translated
into decreased absolute force output (Fig. 2a, d), which correlated
with decreased muscle mass (Fig. 2b, e). However, speciﬁc force
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Fig. 2 Tamoxifen augments the strength of leg muscles of XLMTM mice. Electrically evoked triceps contractions were recorded under isometric conditions
and contractile features analyzed in 42, 84, and 210-day-old mice fed placebo or tamoxifen-supplemented (30mg kg−1) diets. a Average traces showing
absolute phasic (twitch) contraction of the triceps at 42 days (D42). Tamoxifen signiﬁcantly enhanced the force (tension) in Mtm1−/y mice. b Speciﬁc
phasic force (see Online Methods for details) of D42 Mtm1−/y mice augmented with tamoxifen. c Speciﬁc phasic force of Mtm1−/y mice increased with
tamoxifen at all examined ages. d Average traces showing triceps absolute force-frequency curves at D42. Tamoxifen more than doubled the tetanic force
of Mtm1−/y mice. e Speciﬁc force of Mtm1−/y mice markedly augmented with tamoxifen at all stimulation frequencies. f Speciﬁc tetanic force of Mtm1−/y
mice was considerably improved at all studied ages. In triceps examined after various treatment durations, tamoxifen rescued the impaired time to twitch
peak ofMtm1−/y mice (g) but had no impact on the time required for half-relaxation from peak (h). D42 panels: WT wild type; legend in a stands for a, b, d,
e; data represent the mean ± s.e.m. of n= 7 triceps per group. c, f, g, h: black triangles illustrate increasing age (42–84 and 210 days) within each treatment
group; columns from left to right: data represent the mean ± s.e.m. of 7; 8; 7; 7; 7; 13; 7; 0; 0; 7; 8; 6 triceps, respectively. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001;
****P≤ 0.0001; ns non-signiﬁcant, Ø no surviving mice. One-way ANOVA followed by Fisher’s LSD post-test
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was not altered suggesting that intrinsic mechanical properties of
WT myoﬁbers were globally preserved. The speciﬁc phasic and
tetanic tensions of WT mice augmented with age independently
of tamoxifen (Fig. 2c, f).
Tamoxifen improves leg muscle structure and ultrastructure.
Histological analyses showed that the tibialis anterior (TA)
muscle of Mtm1−/y mice contained many ﬁbers in which orga-
nelles, including nuclei and mitochondria, were abnormally dis-
tributed, forming necklace patterns of oxidative staining
essentially in large-caliber ﬁbers41. Tamoxifen did not correct
these speciﬁc features and had a minor impact on ﬁber type
composition (Fig. 3a, b; Supplementary Figure 2). However,
tamoxifen reduced by ~50% the number of myoﬁbers displaying
nuclei in abnormal position, a prominent histological feature of
XLMTM (Fig. 3c). Tamoxifen also induced overall improvement
of the myoﬁbrillar structure, including improved organization of
the Z-lines, highly ordered protein complexes that keep the sar-
comeres in register, and better deﬁned M-line, A-band, and I-
band (Fig. 3d; Supplementary Figure 3).
Tamoxifen reduces disease modiﬁers and alters ER levels. We
examined the consequence of tamoxifen treatment on muscular
transcript and protein levels of targets selected for their known
contribution to CNM pathogenesis, for modulating Mtm1−/y
mouse phenotype, or mediating tamoxifen actions (Fig. 4; Sup-
plementary Tables 4, 5). In the Mtm1−/y mouse, as well in CNM
patients, both BIN1 and DNM2 are overexpressed. Here we
report that BIN1 mRNA is also more abundant in Mtm1−/y
mouse muscle. Overall, in both WT and Mtm1−/y gastrocnemius
muscles, tamoxifen tended to down-regulate BIN1 and DNM2
(Fig. 4a–c), both postulated to act downstream of myotubularin42.
Of note, the ability of tamoxifen to reduce DNM2 levels was
reproduced, at least partly, in a human muscle cell line established
from an XLMTM individual43,44 (Supplementary Figure 4; see
Supplementary Tables 6, 7 for details on the human muscle cell
lines and the primers used for RT-PCR). In mice, tamoxifen also
signiﬁcantly corrected the elevated levels of desmin (a muscle-
speciﬁc intermediate ﬁlament that controls nuclei positioning via
binding myotubularin45), of PI3KC2Β (an enzyme whose genetic
muscle-speciﬁc ablation rescues the disease40) and of dysferlin
(involved in membrane repair and t-tubule biogenesis46,47)
(Fig. 4a, b, d). Muscle extracts from untreated Mtm1−/y mice
massively accumulated a putative dysferlin degradation product
(~160 kDa) whose proportion was reduced to near-normal levels
with tamoxifen (Supplementary Figure 5). Tamoxifen decreased
ERα but not ERβ protein levels, presumably via post-
transcriptional mechanisms since these effects were not mir-
rored by mRNA expression (Fig. 4a, b, e). Tamoxifen also partly
restored sarcomeric myosin content, which was signiﬁcantly
reduced in Mtm1−/y muscle (Fig. 4b, f).
Tamoxifen increases triad density and restores EC coupling.
Well-formed triads are required for efﬁcient calcium release from
intracellular stores and subsequent muscle contraction in
response to nerve stimulation. Tamoxifen restored triad quantity
and improved their morphology (Fig. 5a, b). Consistent with
these ﬁndings, tamoxifen normalized the amplitude of calcium
ﬂuxes elicited by depolarization in myoﬁbers from Mtm1−/y mice
(Fig. 5c–e). Moreover, tamoxifen almost corrected the levels of
DHPR, a voltage-sensitive calcium channel that tightly regulates
excitation–contraction (EC) coupling. The DHPR effector, RyR1,
was found at normal levels in all groups (Fig. 5f–g).
Long-term tamoxifen mitigates myopathic feature progression.
TA muscles of Mtm1−/y mice treated until D84 and D210 still
contained small caliber myoﬁbers with abnormally distributed
organelles (Fig. 6a, b). The diameter of TA myoﬁber signiﬁcantly
increased with age in WT mice while it remained virtually stable
over time in tamoxifen-treated Mtm1−/y mice (Fig. 6c). At D42,
tamoxifen more than halved myoﬁbres with nuclei in abnormal
position in Mtm1−/y mice. Then, these pathological myoﬁbres
gradually accumulated as treated Mtm1−/y mice became older
(Fig. 6d). At D42, tamoxifen reduced by 42%, the deﬁcit in triad
number of Mtm1−/y mice. Between D42 and D210, triad number
declined similarly in both WT and Mtm1−/y-treated mice
(Fig. 6e).
Discussion
XLMTM is a rare myopathy due to the lack of the lipid phos-
phatase myotubularin (MTM1)1,48. Most affected boys die during
early infancy6. Despite extremely high unmet medical need, very
few pharmacological options have been explored so far in animal
models49,50 or in CNM patients51.To date, no approved phar-
macological treatment has been shown to alleviate the symptoms
and increase the life expectancy of the patients.
The rationale for repurposing tamoxifen for XLMTM was
based on previous success of our group with the drug in several
murine models of debilitating muscular diseases, including
mdx5Cv mice, a model of DMD36. We reasoned that the many
protective actions exerted by tamoxifen on diverse muscular
conditions might provide a therapeutic avenue for XLMTM. Our
ﬁndings largely support this view.
In brief, oral tamoxifen, administered from shortly after
weaning (i.e., after Mtm1−/y mice started to develop overt mus-
cular symptoms), improved overall body strength, increased force
generation in leg muscles, slowed disease progression through
clinical stages, and importantly, prolonged the lifespan several-
fold. These functional improvements correlated with reduced
number of centrally located myonuclei, better
excitation–contraction coupling, and normalization of molecular
markers of the disease, all of which likely contribute to tamoxifen-
mediated protection.
Efﬁcient transduction of the muscular action potential into
release of Ca2+ from sarcoplasmic reticulum stores is a critical
step in excitation–contraction coupling (ECC) and a major
determinant of force generation. Triads are key structures in this
process. Triad disorganization and impaired ECC have a major
role in the profound muscle weakness displayed byMtm1−/y mice
and is associated with a decreased level of DHPR52–55. Tamoxifen
not only restored about 42% of triad number deﬁcit in the TA,
but also almost fully normalized DHPR expression and drama-
tically enhanced Ca2+ release in isolated ﬂexor digitorum brevis
(FDB) ﬁbers exposed to a physiological stimulus that triggers
DHPR-mediated RyR activation. Altogether, beneﬁcial actions of
tamoxifen on triad count, structural components, and function
very likely explain the much improved muscle function of
Mtm1−/y mice. The augmented muscle function was measured
not only locally in the triceps, but also at the whole body level
with the grid hanging test, suggesting that tamoxifen-mediated
enhancement of ECC took place in the whole musculature.
Moreover, Mtm1−/y diaphragm weight was gradually increased
over time.
Noteworthy, although body weight deﬁcit was not corrected
and improved muscle structure and muscle force did not reach
WT level, the lifespan of tamoxifen-treated Mtm1−/y mice was
extended by 6.4-fold (45 days median survival of untreated KO vs
290 days) on high dose tamoxifen. Overall, it suggests that the
beneﬁcial effects of tamoxifen on life-sustaining physiological
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functions are sufﬁcient to greatly extend the lifespan of the ani-
mals. Most morphological, functional, and histological outcomes
were stable until around 210 days of age. Preliminary observation
of long-termMtm1−/y mouse survivors (4 mice; average 369 days;
range 271–464 days; i.e., up to 10-fold the median survival of
untreated mice) suggested that the beneﬁcial effects of tamoxifen
persisted on extended periods of time.
Here we also investigated potential molecular mechanisms of
the rescue. Our earlier work with tamoxifen in mdx5Cv mice36
provided evidence that tamoxifen (i) is pro-estrogenic on striated
muscles (as on bone and uterus56), a view supported by a recent
meta-analysis in treated women57, and (ii) exerts beneﬁcial
actions through high afﬁnity estrogen receptors. Typical of
hormone-dependent receptor degradation, binding of tamoxifen
(or its active metabolites) to ERα likely explains the lower levels of
that receptor in muscles of treated Mtm1−/y mice mice58–60.
Myotubularin is intricately linked to BIN1 and DNM2, which
collectively control membrane dynamics from production of
phosphoinositides to membrane curvature and vesicle ﬁssion42.
Noteworthy, mutations in BIN1 and DNM2 cause autosomal
forms of CNM42. MTM1 and BIN1 were proposed to act as
negative regulators of DNM2 in muscle. Accordingly, diminish-
ing DNM2 rescues the phenotype of Mtm1−/y and Bin1−/−
mice15–17. We found that tamoxifen almost normalized BIN1 and
DNM2. On their own, these molecular actions taking place just
downstream of MTM1 might explain most tamoxifen-driven
beneﬁts. Furthermore, we showed that tamoxifen also reduced
DNM2 levels in a human muscle cell line established from an
XLMTM individual43,44. This further demonstrates the value of
the Mtm1−/y mouse as a model for XLMTM15,38–40 and supports
future translation of tamoxifen efﬁcacy ﬁndings from Mtm1−/y
mice to XLMTM patients.
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Interestingly, a recent study in MCF7 cells linked DNM2
reduction to impaired autophagy—a prominent feature in
Mtm1−/y mice39,61—and to ERα accumulation in response to
estradiol62. Although impaired autophagy have been reported in
Mtm1−/y mice, DNM2 levels are usually increased (and not
reduced) in XLMTM and relevant model organisms. In line with
these reports, our observations suggest that other mechanisms
prevail in Mtm1−/y muscle since tamoxifen (i) decreased not only
DNM2 but also ERα levels, and (ii) improved overall muscle
architecture and nuclei positioning, hardly consistent with further
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worsening of autophagic ﬂux subsequent to DNM2 down-
regulation.
Phosphatidylinositol 3-phosphate (PtdIns3P) is a main substrate
of myotubularin and is produced by PI3-kinases including class II
PI3KC2Β. Consistent with the hypothesis that altered PtdIns3P
level account for myotubular myopathy, recent studies showed that
inhibiting or down-regulating PI3KC2Β rescued the phenotype of
Mtm1−/y mice, likely via improvement of ECC40,55. The PI3KC2Β
kinase was over-expressed several-fold in Mtm1−/y gastrocnemius
muscle. Remarkably, we found that tamoxifen almost normalized
PI3KC2Β expression, thereby very likely contributing to the overall
protection exerted by tamoxifen. It is not established, however, if
the reduced levels of PI3KC2B is a direct effect of tamoxifen or if it
is a secondary consequence of an overall improvement of muscle
structure and function. Of note, our ﬁndings on PI3KC2B
levels diverge from those by Dr. James Dowling and colleagues (see
ref. 63), suggesting they might be dependent on the mouse genetic
background and/or disease severity.
Desmin is a muscle-speciﬁc intermediate ﬁlament that shows
discrete sarcomeric expression. It helps maintaining the myoﬁ-
brils in-register and ensuring mechanical integrity of the myoﬁ-
bers during contraction. In Mtm1−/y muscle and in XLMTM
patients, desmin level is increased45,64 and its distribution
resembles that in immature myotubes44,64. Desmin also controls
nuclei and mitochondria positioning, a function that is altered by
mutations in MTM145. We showed here that tamoxifen nor-
malized the elevated levels of desmin in Mtm1−/y mice and this
correlated with improved nuclei position and better sarcomeric
structure, along with partial correction of myosin heavy chain
levels, the major component of myoﬁbrils.
Although tamoxifen signiﬁcantly reduced DNM2, PI3KC2Β
and desmin in muscle of both WT and Mtm1−/y mice, these
molecular changes led to dramatically different consequences. In
Mtm1−/y mice, normalization of elevated levels of these proteins
likely improved the phenotype. By contrast, muscle growth and
function in normal mice was impaired with tamoxifen. We
speculate that this is a consequence of the reduction of these
proteins and of MTM1 to sub-optimal levels. Considering the
roles of the MTM1–BIN1–DNM2 pathway in t-tubule biogenesis
and in excitation-contraction coupling17,52,53,65, it is possible that
muscle cramps experienced by breast cancer patients66–68 result
from tamoxifen-induced changes in the levels of these proteins.
By contrast, we believe that tamoxifen-induced muscle atrophy
observed in WT mice is likely species-speciﬁc as, to our knowl-
edge, alteration of muscle volume has not been reported in
human, not even in breast cancer patients having been on
tamoxifen for several years.
In this study, we show that tamoxifen, given orally to a mouse
model of XLMTM, considerably ameliorated muscle function and
prolonged survival. As reported earlier in a murine model of
DMD36, tamoxifen also caused relative hypertrophy of the
diaphragm of aged Mtm1−/y mice, which warrants further
investigation for assessing the potential beneﬁt on respiratory
function. The most efﬁcacious dose tested (30 mg of tamoxifen
per kg of diet, yielding 4–6 mg of tamoxifen per kg of body weight
per day) was similar to that producing optimal disease prevention
in a mouse model of DMD36. Considering differences in drug
exposure between species, this dose is clinically relevant as it
matches that used for breast cancer therapy, compassionate use
for DMD boys and TAMDMD, the phase 3 clinical trial
(respectively ClinicalTrials.gov identiﬁers NCT02835079 and
NCT03354039). Growth pattern in tamoxifen-treated mice was
not restored to normal, which should be distinguished from a
potential toxicity of tamoxifen on growth. As tamoxifen mod-
ulates molecular events downstream of myotubularin, not all
pathogenic features were corrected to normal values as would be
expected with gene-restoration therapies13. Interestingly, tamox-
ifen has been used as an alternative to growth hormone in short
boys31 and improved predicted adult height in girls with
McCune–Albright syndrome35. Thus, side effects related to sub-
optimal growth of XMLTM patients in future tamoxifen trials are
extremely unlikely.
Interestingly, during the course of our study, Professor James
Dowling and collaborators (Sick Kids Hospital, Toronto, Canada)
made observations similar to ours with tamoxifen in Mtm1−/y
mice, conﬁrming the clinically relevant ﬁndings that we present
here.
Importantly, tamoxifen is a readily available EMA- and FDA-
approved drug used for several decades for treating breast can-
cer19–21. It is also efﬁcacious in other hormone-related dis-
orders22–27and is safe in diverse male pediatric conditions28–35.
We believe that the Orphan Drug Designation recently granted by
the EMA for tamoxifen use in DMD36,37, the launching of the
TAMDMD trial, and simultaneous report of the therapeutic
potential of tamoxifen in Mtm1−/y mice by two independent
groups should encourage priority consideration for clinical eva-
luation for XLMTM. Tamoxifen fulﬁls all criteria18 for timely
repurposing as a symptomatic treatment for XLMTM, either as a
monotherapy or combined with AAV-MTM1 restoration or
DNM2 downregulation approaches that will hopefully prove
efﬁcacious in clinical trials. Tamoxifen might also prove useful in
other myopathies where t-tubule defects secondary to increased
DNM2 levels contribute to the pathogenesis, such as BIN1-related
CNM and caveolin-3 and dysferlin-related myopathies15,17,65,69.
Methods
Animals and housing conditions. All procedures involving mice complied with
the Swiss Federal Law on Animal Welfare. Procedures were reviewed by the
veterinary ofﬁce of Geneva and authorized under the license numbers GE/61/16
and GE/13/17.
Mtm1-deﬁcient mice in the 129Pas genetic background were obtained from Dr.
J. Laporte (IGBMC, Illkirch, France). A colony was established and maintained at
the animal facility of the Geneva-Lausanne School of Pharmaceutical Sciences by
Fig. 4 Tamoxifen reduces the expression of XLMTM disease modiﬁers and alters the expression of estrogen receptors. The mRNA and protein levels of
known XLMTM disease modiﬁers and of estrogen receptors, which mediate most tamoxifen actions, were determined in gastrocnemius muscle of 42-days
old (D42) wild type (WT) andMtm1−/y mice, either untreated (control; Ctrl) or tamoxifen (TAM)-treated (30mg kg−1 of diet). a mRNA levels normalized
to glyceraldehyde-3-phosphate dehydrogenase (Gapdh). From left to right, relative expression (as percentage of WT Ctrl) of mRNA encoding amphiphysin
2/BIN1 (Bin1; all transcripts), muscle-speciﬁc BIN1 (Bin1; exon 11-containing transcript), dynamin-2 (Dnm2), PI3KC2B (Pik3c2b), estrogen receptor (ER) α
(Esr1), and ERβ (Esr2). b Representative immunoblots of proteins of interest, as indicated. DNM2: dynamin 2; MyHC: myosin heavy chains; GAPDH:
glyceraldehyde-3-phosphate dehydrogenase. Position of molecular weight markers (kDa) is shown. c–f Levels (normalized to GAPDH and expressed as
percentage of WT Ctrl) of proteins selected for their role in XLMTM and tamoxifen signaling. c Proteins involved in the “MAD”-pathway. From top to
bottom: myotubularin (MTM1), amphiphysin 2/BIN1 (pan-isoforms), amphiphysin 2/BIN1 (muscle-speciﬁc isoform), dynamin-2 (DNM2). d Other disease
modiﬁers and protein deregulated in absence of MTM1. From top to bottom: desmin, dysferlin, PI3KC2B. e Estrogen receptors. Top: ERα; bottom: ERβ. f
Myosin heavy chains, a major constituent of sarcomeres. Data represent the mean ± s.e.m. of n= 6–8 muscles per group. *P≤ 0.05; **P≤ 0.01; ***P≤
0.001; ****P≤ 0.0001; ns non-signiﬁcant. One-way ANOVA followed by Fisher’s LSD post-test
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breeding wild type males with Mtm1+/− heterozygous females. The Mtm1+/y (wild
type) and Mtm1−/y (mutant) males in the progeny were used in experiments. Mice
were housed on wood granule bedding in either Eurostandard type II or type III
polycarbonate cages equipped with ﬁlter tops (Indulab AG, Gams, Switzerland).
They were kept on a 12-h dark/12-h light cycle, under constant temperature (22 ±
1 °C) and humidity (50–60%). Mice were allowed unlimited access to food and
water throughout the study. Environment enrichment consisted in a Mouse House
(Indulab AG), shredded paper, and cylinders of pure cellulose (Cocoon, Datesand,
Manchester, UK).
Genotyping. Toe biopsies were taken at 7–10 days post-natal for combined gen-
otyping and permanent marking of individuals. DNA was prepared using
DirectPCR Lysis Reagent/Mouse Tail (AxonLab AG, Le Mont-sur-Lausanne,
Switzerland) according to the manufacturer’s instructions. The ﬁnal lysate was
diluted ﬁvefold in molecular biology grade water. One μL of DNA was used for
PCR ampliﬁcation using ready to load 2x GoTaq® Master Mix (Promega,
Dübendorf, Switzerland). The following primers (Microsynth AG, Balgach, Swit-
zerland) were added: MTM1 Forward 1 (5′-AGACAGTGATGCAC
AGAGAGGAG-3′), binding upstream of exon 4 (used at 0.25 μM); MTM1
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tubule (tub) ﬂanked by terminal cisternae (cis) arising from the sarcoplasmic reticulum and controlling Ca2+ release—were visualized by transmission
electron microscopy (TEM) in the tibialis anterior (TA) of mice at D42. Note the abnormal shape of the remaining triads in the Mtm1−/y mouse and
recovery with tamoxifen treatment. The bar represents 100 nm. b The number of well-positioned triads per sarcomere unit was determined from TEM
pictures in TA from wild type (WT) and Mtm1−/y mice at D42. TAM partly rescued the much decreased triad density inMtm1−/y mice. Mean ± s.e.m. of n
= 2–3 mice. c–e Excitation–contraction coupling assessed via live imaging of Ca2+ ﬂuxes induced by KCl depolarization in single FDB myoﬁbers (see Online
Methods for details). c Average traces of the responses of FDB ﬁbers to KCl, an experimental setting that mimics muscle depolarization (n= 17–29 ﬁbers).
d Representative images (pseudo-colored) illustrating cytosolic Ca2+ levels in FDB ﬁbers at baseline (−; before KCl pulse) and at the peak of KCl-induced
response (+). The bar represents 100 μm. e Quantiﬁcation of cytosolic Ca2+ at the peak response. TAM enhancedMtm1−/y cytosolic Ca2+ to levels found
in WT. Data shown in e represent, from left to right, the mean ± s.e.m. of n= 29, 53, 53, and 31 ﬁbers. f Representative western blots of DHPR and RyR1. g,
h Quantiﬁcation of DHPR and RyR1, respectively. Mean ± s.e.m. of n= 7 muscles. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001; ns non-signiﬁcant.
One-way ANOVA followed by Fisher’s LSD post-test
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Forward 2 (5′-AATGGCCCCATTAAGGGAAG-3′), binding within exon 4 (used
at 0.50 μM); MTM1 Reverse (5′-GTGTGCATGTTTGGACCATGG-3′), binding
downstream of exon 4 (used at 0.50 μM). The PCR reaction (10 μL ﬁnal volume)
was run on a Biometra Tpersonal thermocycler (AxonLab) as follows: initial
denaturation at 95 °C for 5 min; ampliﬁcation: denaturation at 95 °C for 20 s,
annealing at 55 °C for 30 s, elongation at 72 °C for 60 s, 35 cycles; ﬁnal elongation at
72 °C for 5 min; holding temperature, 10 °C. PCR products were analyzed on 1%
agarose gels containing SYBR Safe DNA Gel Stain (Thermo Fisher Scientiﬁc AG,
Reinach, Switzerland), at a 1:20,000 dilution. The mutant allele was identiﬁed as a
band of 165 bp and the wild type one as a band of 437 bp (a band of 920 bp arising
from the primers binding outside exon 4 was expected but not efﬁciently
ampliﬁed).
Groups and treatments. Mtm1+/− carrier females are clinically healthy. Only
male mice were used in experiments. Male pups were weaned on post-natal day 23
± 1, at which time treatments were initiated. Randomization was not feasible
because small cohorts were generally produced and each group had to comprise
enough wild type mice to foster the mutants. Sub-groups of mice, usually made of
2–4 wild type and 1–4 Mtm1−/y mice, were given pellets of diet supplemented with
different amounts of tamoxifen citrate (Haohua Industry Co., Jinan City, China) to
achieve to 3, 10, and 30 mg of tamoxifen free base per kg of chow. The modiﬁed
chow was prepared by Cargill, Provimi-Kliba AG (Kaiseraugst, Switzerland).
Speciﬁc care was systematically implemented in order to restrict suffering of the
fragile Mtm1−/y mice. This included food pellets placed inside the cages, bottles
equipped with long nozzles, bedding granules to raise the ground and facilitate
access to drinking water, nestling and enrichment materials, and non-experimental
chaperone mice in case not enough wild type littermates were generated along with
the Mtm1−/y mice.
For survival analyses, mice were followed up to 200–210 days of age. For the
other experiments, treatments were maintained until post-natal day 42 (±1) days
(D42, young mice), at which time around 60% of the untreatedMtm1−/y mice were
still alive; 84 (±2) days (D84, adult mice), at which time none of the untreated
Mtm1−/y mice survived; and 210 (±3) days (D210, old mice).
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07058-4
10 NATURE COMMUNICATIONS |          (2018) 9:4848 | DOI: 10.1038/s41467-018-07058-4 | www.nature.com/naturecommunications
Longitudinal monitoring of disease progression. Body weight, food consump-
tion, and clinical score were recorded three times per week on each sub-group of
mice. Food consumption (in g diet per g body weight per day) was calculated from
the amount of diet (in g) consumed by each cage (average total body weight in g)
during periods of 2–3 consecutive days. Disease progression was assessed three
times per week using a clinical grade scale adapted from that described earlier38. In
brief, the mice were given a score of 1 (normal function of hind limbs), 2 (difﬁculty
in spreading toes), 3 (evident weakness in legs), 4 (paralysis of one hind limb), or 5
(both hind limbs are paralyzed). Moribund mice were killed, usually soon after
reaching stage 5.
Mice were subjected once a week to a horizontal grid-hanging test that
measured their ability to sustain their own body weight against gravity. In
brief, a mouse was placed on the center of a wire grid (dimension 35 × 50 cm,
made of 1 mm-diameter metal wire and forming a 1.26 cm square mesh). The
grid was gently inverted upside-down and maintained approximately 50 cm
above a thick layer of soft bedding material to avoid causing damage to the
animals in case of fall. The time until which the mouse fell from the grid was
recorded. In the event of a fall, the timer was stopped, the grid put back to its
original position, the mouse promptly returned to the grid and the test was
continued. The test was ended when the ﬁnal time score (set at 60 s) was reached
or when the mouse was not able to hold the grid for more than 10 s between
consecutive falls.
Electrically evoked contractions of the triceps surae. Muscle mechanical
properties of the triceps surae (hereafter referred to as “triceps”) were recorded
in situ in deeply sedated, freely breathing mice without disturbing triceps inner-
vation and blood supply. The triceps is a large muscle group that makes up most of
the calf volume and comprises the gastrocnemius, the plantaris and the soleus
muscles. Its balanced composition of slow- and fast-contracting ﬁbers makes it
similar to most human leg muscles, hence its value for physiology, experimental
pharmacology and evaluating therapeutics. In an isometric setting such as the one
we used, the muscle is set to a ﬁxed length. Electrical stimulation causes attempts of
the muscle to contract; the mechanical tension (“force”) exerted on its extremities
is measured via a force transducer. Meaningful parameters are determined from
two extreme mechanical responses that are phasic and tetanic contractions. A
phasic (also known as twitch) contraction consists in an elementary muscle con-
traction, comprising a rising phase followed by full muscle relaxation (return to
baseline), from which kinetics of contraction and relaxation can be calculated. The
phasic force is measured as the amplitude of the response (see Fig. 2a, b in the main
text). On the other end of the spectrum, stimulating the muscle at high frequency
generates a tetanic contraction, which is the maximum force that the muscle can
produce (Fig. 2d, e).
At the end of the treatment period, mice were brieﬂy sedated by inhalation of
isoﬂurane before i.p. injection of a mixture of urethane–diazepam–buprenorphine
(1.5 g kg−1, 5 mg kg−1, and 100 μg kg−1, respectively), ensuring deep anesthesia
and adequate analgesia for over 2 h. Mechanical responses of the right triceps to
electrical stimulations were recorded isometrically using a custom-made device as
previously described36,70–74. In brief, the knee joint was ﬁrmly immobilized, and
the Achilles tendon was linked to a force transducer coupled to a LabView interface
(National Instruments, Austin, TX). Two thin steel electrodes were inserted into
the triceps for delivering 0.5-ms pulses of controlled intensity and frequency. After
manual settings of optimal muscle length and optimal current intensity, 5–6 phasic
responses to single stimuli were recorded at a sampling rate of 3 kHz to determine
absolute peak twitch tension, time to peak twitch tension and time for half
relaxation from peak twitch tension. Then, force–frequency curves were
constructed at a sampling rate of 1 kHz: the triceps was subjected to 200-ms trains
of stimuli at increasing frequencies (10 to 120 Hz by increments of 10 Hz, then 150
and 200 Hz) delivered at 30-s intervals. The maximum response was taken as the
absolute tetanic tension. Absolute phasic and absolute tetanic tensions were
converted into speciﬁc tensions (in mNmm−2 of muscle section) after
normalization for the muscle cross-sectional area. The cross-sectional area (in
mm2) was determined by dividing the triceps mass (in mg) by the product of the
optimal muscle length (in mm) and the density of mammalian skeletal muscle
(1.06 mgmm−3).
Blood and tissue sampling. Immediately after isometric force recordings, mice
were thoracotomized, heparin (LKT labs, Enzo Life Sciences, Lausen, Switzerland)
(MW 4–6 kDa; 30 μL; 30 UmL−1) was injected into the heart, and the descending
aorta was cut. Total blood was collected in a 1.5-mL microcentrifuge tube, and
centrifuged (10 min, 4 °C, 10,000×g). Plasma was snap-frozen in liquid nitrogen
before being stored at −80 °C. Volumes of total blood and plasma were recorded.
Selected muscles were quickly dissected and weighed (Supplementary Table 2 and
3). Tibialis anterior (TA) were processed for histology and transmission electron
microscopy. The gastrocnemius were saved for RT-PCR and western-blot analyses.
The remaining leg muscles were collected and pooled. That muscle bulk was saved
for determining levels of tamoxifen and its metabolites. In some instances, ﬂexor
digitorum brevis (FDB) muscles were used for live imaging of calcium ﬂuxes in
single intact ﬁbers.
Histological analysis of skeletal muscle. TA muscles were embedded in traga-
canth gum (Sigma-Aldrich) (5% w/v in water), frozen in liquid nitrogen-cooled
isopentane and stored at −80 °C until further processing. Air-dried 10 μm-thick
transverse sections were ﬁxed with 4% PFA and stained with hematoxylin and
eosin (HE) or for succinate dehydrogenase (SDH) activity using conventional
procedures16,17. Image acquisition was performed with a NanoZoomer 2.0-HT
slide scanner equipped with the ﬂuorescence module L11600–21 (Hamamatsu
Photonics). Myoﬁber cross-sectional area (CSA) was analyzed using FIJI image
analysis software (ImageJ 1.51s version, available at http://imagej.net/) from
ﬂuorescence pictures taken from HE-stained TA sections. CSA (μm2) was deter-
mined from at least 300 ﬁbers per muscle. The percentage of myoﬁbers with
abnormally positioned nuclei (either centralized or internalized) was calculated
from at least 300 ﬁbers per TA using the cell counter plugin in FIJI analysis
software. The total number of myoﬁbers in each TA was also counted using FIJI.
Transmission electron microscopy. The proximal half of TA muscles was cut into
small pieces that were ﬁxed with 2.5% glutaraldehyde, 2.5% paraformaldehyde and
50 mM CaCl2 in 0.1 M cacodylate buffer (pH 7.2). Samples were post-ﬁxed with 2%
OsO4, 0.8% K3Fe(CN)6 in 0.1 M cacodylate buffer (pH7.4) for 2 h a t 4 °C and
incubated with 5% uranyl acetate for 2 h at 4 °C. Muscles were dehydrated in a
graded series of ethanol and embedded in epon resin. Thin (70-nm) sections were
stained with uranyl acetate and lead citrate and examined by transmission electron
microscope. The number of triads per sarcomere (around 40 per mouse) was
quantiﬁed from electron micrographs using the Metamorph 3 software15,75. The
ratio of triads/sarcomere was calculated by dividing number of triads clearly
identiﬁed and correctly localized by the total number of sarcomeres present in the
image15,76.
Analysis of mRNA expression by quantitative RT-PCR. The left gastrocnemius
muscle (non-exposed to the isometric contraction protocol) was snap-frozen in
liquid nitrogen and stored at −80 °C until processed for quantitative PCR (qPCR)
essentially as described36. The muscles were ground to a ﬁne powder in mortars
cooled in liquid nitrogen. RNA were extracted from approximately 10 mg of
muscle powder using RNeasy Fibrous Tissue mini kit (Qiagen, Hombrechtikon,
Switzerland). Tissue disruption was enhanced by sonicating three times for 3 s on
ice. Then 100 ng of total RNA were reverse-transcribed with Super-Script II
Reverse Transcriptase (Invitrogen). The resulting cDNA was subjected to quanti-
tative PCR (qPCR) ampliﬁcation using PowerUp SYBRTM Green Master mix
(Applied Biosystems, Thermo Fisher Scientiﬁc) according to the manufacturer’s
instructions. Brieﬂy, 10 μL reaction mixtures were prepared containing 1 μL of
cDNA (equivalent to 2.5 ng of initial RNA), forward and reverse primers (500 nM
each) for Bin1 (pan isoforms), Bin1 (isoform 8), Dnm2, Esr1, Esr2, Pik3c2b or
Gapdh (used as the housekeeping gene) (Supplementary Table 4), the kit Master
mix and RNAse-free water. They were subjected to PCR ampliﬁcation using a
StepOnePlus Real-Time PCR System thermocycler (Thermo Fisher Scientiﬁc)
under the following conditions: initial denaturation at 95 °C for 60 s; ampliﬁcation:
denaturation at 95 °C for 20 s, annealing at 55 °C for 30 s, elongation at 72 °C for
60 s, 40 cycles; ﬁnal elongation at 72 °C for 5 min. The expression level of each
transcript was expressed relative to that of Gapdh using the 2−ΔΔCt method36.
Semi-quantitative western-blots. Gastrocnemius muscles were pulverized on
liquid nitrogen and extracts were prepared as previously described36,73,74. The ﬁnal
protein concentration was adjusted to 3 mgmL−1 with reducing Laemmli buffer.
Muscle extracts (30 to 60 μg per lane) were resolved by SDS-PAGE, and proteins
were transferred onto nitrocellulose membranes using standard procedures. Equal
loading and transfer efﬁciency were veriﬁed with Ponceau Red staining. Mem-
branes were blocked for 1 h in TBST (20 mM Tris-base, 150 mM NaCl, 0.05%
Tween-20, pH 7.5) containing 5% non-fat dry milk and incubated overnight at 4 °C
with one of the primary antibodies listed in Supplementary Table 5.
After extensive wash in TBST, the membranes were incubated with a HRP-
conjugated secondary reagent (Donkey anti-Rabbit (Amersham, GE Healthcare Life
Sciences, Thermo Fisher Scientiﬁc), Goat anti-mouse (Bio-Rad), or kappa light chain
binding protein (Santa Cruz Biotechnologies)) as required before signal detection on
X-ray Fuji ﬁlms (Thermo Fisher Scientiﬁc) using an enhanced chemiluminescence kit
(ECL Prime Western Blotting Detection Reagent) (Amersham). The X-ray ﬁlms were
scanned at high resolution (720 dpi) on an Epson Perfection V750 PRO scanner using
settings for transparent documents in order to avoid signal saturation and augment
the linear range of the signals. Bands were quantiﬁed using ImageJ (version 1.48;
freely available at http://imagej.nih.gov/ij). Speciﬁc care allowing semi-quantitative
analysis has been described in details elsewhere36,74. Brieﬂy, in order to allow intra-gel
and inter-gel comparison and semi-quantitative analysis of the signals, the following
procedure was applied: (i) for each muscle protein to be quantiﬁed, 4 gels were run
simultaneously (PerfectBlue™ Dual Gel System Twin ExW S, Peqlab) and processed in
parallel, (ii) the samples (6–8 muscles per group) were loaded as quadruplets, each
consisting of extracts from non-treated and TAM-treated WT and non-treated and
TAM-treatedMtm1-null mice (iii) each quadruplet was ﬂanked by a standard extract
(Std), consisting of a mixture of all muscle extracts, (iv) the portions of the gels that
contained the protein of interest were transferred onto a single nitrocellulose
membrane, ensuring that all samples and ﬂanking standard extracts were
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simultaneously exposed to the blocking solution, primary antibodies, secondary HRP-
conjugated secondary antibody, ECL reagent, and X-ray ﬁlm. Signals were normalized
to GAPDH and the resulting values were normalized to that of the ﬂanking standard
samples. The standard sample being a mixture of all samples to be compared the ones
with the others, this ensured that its signal has an average, non-saturating, intensity.
Finally, the values were expressed as the percentage of the WT control group.
Larger views of the blots for which portions are shown in Figs. 4 and 5 are
presented in Supplementary Figure 6.
Culture of isolated ﬂexor digitorum brevis (FDB) ﬁbers. Hind feet were dis-
sected and immersed in transfer buffer (Hank’s buffered salt solution supple-
mented with 10 mM HEPES, pH 7.4). FDB muscles were dissected under a
binocular microscope, transferred to warmed (37 °C) maintenance medium (Dul-
becco’s Modiﬁed Eagle’s Medium (DMEM) containing 10% fetal bovine serum and
10 μg mL−1 ciproﬂoxacin (Sigma)), and 1 mgmL−1 collagenase type IA (Sigma)
was ﬁnally added77. The full process took no more than 1 h. The mixture was
maintained for 60 min at 37 °C with frequent shaking in a humidiﬁed incubator
gassed with air containing 5% CO2. Then, muscles were carefully rinsed twice in
warmed maintenance medium to remove enzyme excess and individual ﬁbers were
released by triturating gently with ﬁre-polished Pasteur pipettes of decreasing
opening widths. Throughout that process, aliquots of maintenance medium con-
taining single ﬁbers were transferred onto clean 18 mm-diameter glass coverslips
coated with 15 μg cm−2 Matrigel (BD biosciences) in 12-well tissue culture plates.
Ca2+ measurement was performed the next day.
Live imaging of cytosolic calcium in FDB ﬁbers. Ca2+ levels in the cytosol of
FDB ﬁbers was monitored via ﬂuorescence microscopy using the calcium-sensitive
probe Fura-2 essentially as described previously77. Fura-2-AM (Molecular Probes,
Invitrogen, Thermo Fisher Scientiﬁc), the acetoxymethyl ester of Fura-2, was used
to facilitate loading into ﬁbers and the subsequent de-esteriﬁcation and intracel-
lular trapping. The Fura-2-AM stock solution was prepared extemporaneously by
mixing Fura-2-AM (5 mM) with an equal volume of Pluronic acid F-127 (20% w/v
solution, Molecular probes). Fibers were washed twice with physiological salt
solution containing Ca2+ (PSS+; composition in mM: HEPES 5, KCl 5,
MgCl2·6H2O 1, NaCl 145, CaCl2·2H2O 1.7, glucose 10) before incubation in the
loading solution (PSS+ containing 2 μLmL−1 of the Fura-2-AM/Pluronic acid
working solution; ﬁnal Fura-2 concentration 5 μM). Loading was done at 37 °C for
45 min after which the cells were washed twice with PSS+ and Fura-2-AM allowed
to de-esterify at room temperature for another 20 min. Loading and de-
esteriﬁcation buffers were supplemented with 100 μM N-benzyl-p-toluenesulfo-
namide (BTS) (Medchem Express, Lucerna-Chem, Luzern, Switzerland) to prevent
ﬁber contraction and detachment. All loading steps were done in the dark. Cov-
erslips holding ﬁbers were placed in a perfusion chamber that was continuously
perfused at 1.5 mLmin−1 using a peristaltic pump. The imaging setup consisted of
a high speed monochromator (Visitron Systems, Puchheim, Germany) allowing
selection of alternating excitation wavelengths and an ORCA-Flash4.0LT Digital
sCMOS camera mounted on an Axiovert 200 microscope (Carl Zeiss AG, Feldbach,
Switzerland) equipped with objectives for high resolution ﬂuorescence imaging.
The experiments were done ratiometrically with alternating excitation wavelengths
of 340 and 380 nm and emission at wavelengths above 510 nm using a long pass
ﬁlter. Images were acquired every 2 s. After recording baseline calcium, ﬁbers were
perfused with a modiﬁed PSS+ containing high concentration of KCl (125 mM)
and reduced concentration of NaCl (10 mM). Ca2+ increment during depolariza-
tion was calculated as the difference between resting Ca2+ levels and the maximum
levels of Ca2+ reached during depolarization. Data acquisition and analysis was
performed using VisiView software version 3.3.0.3 (Visitron Systems).
Data analysis and statistics. Survival curves were analyzed using the Log-rank
(Mantel–Cox) test. All other comparisons were assessed by ANOVA followed by
Fisher’s least signiﬁcance difference (LSD) test. The overall changes in body
weights, grid test scores and clinical grades over time were assessed from the areas
under the curves calculated from every mouse.
Data availability
The authors declare that all data supporting the ﬁndings of this study are available
within the paper and its supplementary information ﬁles. A reporting summary for
this Article is available as a Supplementary Information ﬁle.
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